Targeted chelation therapy decreases NLRP3 expression by vascular cells and acts as senomorphic in chronic kidney disorder induced vascular calcification
For the first time, the current study provides proof of concept on the senotherapeutic potential of a targeted chelation therapy and its capacity to modulate SASP from the senescent cells accumulated in calcified aorta.
Authors
- Naren Vyavahare (ORCID: https://orcid.org/0000-0002-4889-6542)
- Fatema Tuj Zohora (ORCID: https://orcid.org/0000-0003-2769-9256)
- Gregory Halsey
- Shivani Arora (ORCID: https://orcid.org/0000-0002-7332-9953)
- Alyssa Swiss
Institutions
- Virginia Commonwealth University (US)
- Yale University (US)
- Enveda Therapeutics (United States) (US)
- Clemson University (US)
Publication Details
- Journal
- International Journal of Immunopathology and Pharmacology
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1177/03946320251391142
- Citations
- 1
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.43